Back to Dashboard
DSKYF · Healthcare

Daiichi Sankyo Company, Limited

Asia Healthcare
Market cap
$33.3B
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
OTC Markets OTCPK
About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the…

Congressional trades · 1 on record
Disclosures from 2025-07-03 to 2025-07-03
The newest disclosure we hold for this stock is 2025-07-03. That is the end of our data, not necessarily the end of the trading — our bulk STOCK Act archive stops there and newer filings arrive through a separate live feed. Treat the absence of recent rows as “not covered”, not as “no trades”.
Trade date Member Chamber Action Amount
2025-07-03 Gilbert Ray Cisneros, Jr. · D-CA House Sold $1,001 - $15,000
Not in our coverage. Daiichi Sankyo Company, Limited isn't currently held by any of the 50 hedge funds we track. The price chart and company profile below come from public Yahoo Finance data.
Price History
Loading price data...
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell Daiichi Sankyo Company, Limited or any security.

订阅每周更新

我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费,直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订